Tuesday, March 6th 2012 at 3:00 pm by Sayer
Over a quarter of a century ago a study was performed on the seeds
of the Soursop fruit, also known as graviola, which at that time demonstrated
such amazing cancer-fighting potential, that those exposed to it within the
conventional medical community looked upon it with complete incredulity.
Published in the
Journal of Natural Products in 1996,
Compound 1, one of five extracted from the seed of the graviola fruit, was found
to be “selectively cytotoxic to colon adenocarcinoma cells (HT-29) in which it
was 10,000 times the potency of adriamycin.” [emphasis added]
Adriamycin is the trade name for the chemoagent doxorubucin and is
known by the nickname “red devil,” due to both its deep red color and terrible
side effects, which include life-threatening, even fatal damage to the
cardiovascular system. This abject lack of “selective cytotoxicity” — the
ability to kill only the cancer cells and not healthy ones — is what makes
Adriamycin so dangerous. And yet, it has been a first line treatment for a wide
range of cancers for almost half a century.
Since the 1996 study, little research on graviola was performed.
There was a
cell study in 1999 which showed it had anti-prostate and breast cancer activity;
cell study showed that graviola
exhibited anti-hepatoma (liver cancer) activity, but nothing as promising as the
original 1996 study ever followed.
Then, in 2011, the journal Nutrition and Cancer revealed
highly promising research on Graviola
and breast cancer. Researchers found that graviola fruit extract (GFE)
suppressed so-called oncogene (or cancer-causing gene) expression in the cell
and animal models of breast cancer. The oncogene known as epidermal growth
factor receptor (EGFR) is commonly over-expressed in breast cancer, and
therefore an ideal target for therapy.
According to the researchers:
“A a 5-wk dietary treatment of GFE (200 mg/kg diet) significantly
reduced the protein expression of EGFR, p-EGFR, and p-ERK in MDA-MB-468 [breast
cancer] tumors by 56%, 54%, and 32.5%, respectively. Overall, dietary GFE
inhibited tumor growth, as measured by wet weight, by 32% (P < 0.01).”
The study authors concluded:
“These data showed that dietary GFE induced significant growth
inhibition of MDA-MB-468 cells in vitro and in vivo through a mechanism
involving the EGFR/ERK signaling pathway, suggesting that GFE may have a
protective effect for women against EGFR-overexpressing BC [breast cancer].”
Given these findings the time may be ripe for reconsideration of
graviola in the prevention and/or treatment of cancers, such as colon and breast
This article is not intended to provide medical advice, diagnosis or treatment.
Views expressed here do not necessarily reflect those of GreenMedInfo or its